43 min
Improving Clinical Research and Trials Through Pharma/Advocacy Partnerships PharmaTalkRadio
-
- Science
This podcast moderated by Mary Murray, BMS and recorded at the 6th annual Patients as Partners US conference discusses Improving Clinical Research and Trials Though Effective Pharma/Advocacy Partnerships.
Topics include:
What are the key elements that make for an effective partnership between Industry and Advocacy Groups?What is not getting done or being left on the table to increase partnership value?In relation to clinical trials what can we and what must we learn from existing experiences in patient engagement that will help provide patients with the enhanced active role they deserve?From an industry perspective there are generally three key decision-making points: research priority setting, design of clinical trials, and early dialogue that can benefit from vaiours levels of patient engagement - are there other valuable areas we are missing hereFrom a patient advocacy group perspective in which areas should industry be improving its clinical research, trial development and planning?
Panelists include:
Ellen Miller-Sonet, CancerCareKristin Smedley, Curing Retinal Blindness FoundationTiffany Westrich-Robertson, International Foundation for Autoimmune & Autoinflammatory Arthritis (IFAA)Keri Yale, Boehringer Ingelheim
To learn more about the 7th annual Patients as Partners US conference taking place June 29-30, 2020 in Philadelphia, PA please visit theconferenceforum.org
This podcast moderated by Mary Murray, BMS and recorded at the 6th annual Patients as Partners US conference discusses Improving Clinical Research and Trials Though Effective Pharma/Advocacy Partnerships.
Topics include:
What are the key elements that make for an effective partnership between Industry and Advocacy Groups?What is not getting done or being left on the table to increase partnership value?In relation to clinical trials what can we and what must we learn from existing experiences in patient engagement that will help provide patients with the enhanced active role they deserve?From an industry perspective there are generally three key decision-making points: research priority setting, design of clinical trials, and early dialogue that can benefit from vaiours levels of patient engagement - are there other valuable areas we are missing hereFrom a patient advocacy group perspective in which areas should industry be improving its clinical research, trial development and planning?
Panelists include:
Ellen Miller-Sonet, CancerCareKristin Smedley, Curing Retinal Blindness FoundationTiffany Westrich-Robertson, International Foundation for Autoimmune & Autoinflammatory Arthritis (IFAA)Keri Yale, Boehringer Ingelheim
To learn more about the 7th annual Patients as Partners US conference taking place June 29-30, 2020 in Philadelphia, PA please visit theconferenceforum.org
43 min